107.66
前日終値:
$105.01
開ける:
$106.75
24時間の取引高:
627.56K
Relative Volume:
0.83
時価総額:
$6.25B
収益:
$507.44M
当期純損益:
$-187.69M
株価収益率:
-32.91
EPS:
-3.271
ネットキャッシュフロー:
$-39.06M
1週間 パフォーマンス:
+2.31%
1か月 パフォーマンス:
-10.58%
6か月 パフォーマンス:
+32.02%
1年 パフォーマンス:
+9.39%
Glaukos Corporation Stock (GKOS) Company Profile
Compare GKOS vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
GKOS
Glaukos Corporation
|
107.66 | 6.10B | 507.44M | -187.69M | -39.06M | -3.271 |
|
ABT
Abbott Laboratories
|
102.67 | 177.03B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
328.59 | 124.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
86.65 | 110.08B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
62.75 | 93.53B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
80.08 | 45.84B | 6.07B | 1.06B | 1.34B | 1.8063 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-27 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-10-01 | 開始されました | Goldman | Buy |
| 2025-05-01 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | アップグレード | Mizuho | Neutral → Outperform |
| 2024-12-11 | アップグレード | Citigroup | Neutral → Buy |
| 2024-12-06 | 開始されました | UBS | Buy |
| 2024-12-02 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-05-06 | アップグレード | Jefferies | Hold → Buy |
| 2023-12-21 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-12-04 | 開始されました | Morgan Stanley | Equal-Weight |
| 2023-11-28 | 開始されました | Truist | Buy |
| 2023-11-08 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | 開始されました | Mizuho | Neutral |
| 2022-12-19 | アップグレード | JP Morgan | Underweight → Neutral |
| 2022-12-12 | アップグレード | Citigroup | Neutral → Buy |
| 2022-10-14 | 再開されました | Stephens | Overweight |
| 2022-10-04 | 開始されました | Needham | Buy |
| 2022-07-12 | アップグレード | Stifel | Hold → Buy |
| 2022-02-03 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | アップグレード | BTIG Research | Neutral → Buy |
| 2021-11-03 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | ダウングレード | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-07-14 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-01-29 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | アップグレード | Citigroup | Sell → Neutral |
| 2020-12-09 | 開始されました | Oppenheimer | Perform |
| 2020-11-17 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-06-15 | 開始されました | Jefferies | Hold |
| 2020-03-05 | 開始されました | Citigroup | Sell |
| 2020-02-28 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-01-06 | アップグレード | Berenberg | Hold → Buy |
| 2019-12-12 | ダウングレード | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | ダウングレード | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | 開始されました | BTIG Research | Neutral |
| 2018-08-30 | 開始されました | Berenberg | Hold |
| 2018-08-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-08-03 | 繰り返されました | Stifel | Hold |
| 2018-06-21 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-04-13 | ダウングレード | Stifel | Buy → Hold |
| 2018-03-01 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2017-03-02 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2017-01-06 | アップグレード | Stifel | Hold → Buy |
| 2016-10-27 | 開始されました | Wells Fargo | Outperform |
すべてを表示
Glaukos Corporation (GKOS) 最新ニュース
Glaukos Corp. Experiences Evaluation Revision Amidst Mixed Market Signals and Volatility - Markets Mojo
Alex Thurman: ‘Phenomenal Year’ for Glaukos - Orange County Business Journal
Price-Driven Insight from (GKOS) for Rule-Based Strategy - Stock Traders Daily
Aug Chart Watch: Does Glaukos Corporation stock have upside surprise potential2026 Major Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Glaukos breaks ground on $80M R&D, manufacturing facility in Alabama - MSN
Glaukos (NYSE:GKOS) CFO Sells $267,321.06 in Stock - MarketBeat
Glaukos SVP Thurman sells $267k in GKOS stock - Investing.com
Glaukos (NYSE: GKOS) president reports new stock and option grants - Stock Titan
GLAUKOS (GKOS) CDO Tomas Navratil earns performance RSU stock awards - Stock Titan
Glaukos Corporation (NYSE:GKOS): Is Breakeven Near? - 富途牛牛
Glaukos launches Epioxa, boosts growth in corneal treatments - MSN
Riverbridge Partners LLC Sells 34,475 Shares of Glaukos Corporation $GKOS - MarketBeat
Assenagon Asset Management S.A. Has $20.59 Million Stock Position in Glaukos Corporation $GKOS - MarketBeat
Glaukos (GKOS) Is Up 5.5% After Launching Incision-Free Epioxa Therapy For KeratoconusWhat's Changed - simplywall.st
Vanguard realigns reporting; Vanguard subsidiaries to report GKOS holdings (GKOS) - Stock Titan
Insider Selling: Glaukos (NYSE:GKOS) CFO Sells 1,521 Shares of Stock - MarketBeat
Glaukos CFO Thurman sells $160k in shares By Investing.com - Investing.com Australia
Glaukos CFO Thurman sells $160k in shares - Investing.com
Glaukos (NYSE: GKOS) CDO has shares withheld to cover tax obligations - Stock Titan
Glaukos (NYSE: GKOS) CFO sale and tax share withholdings detailed - Stock Titan
Glaukos (NYSE: GKOS) insider plans sale of 2,511 vested shares - Stock Titan
Glaukos (GKOS) affiliate files to sell 1,521 shares after vesting - Stock Titan
Glaukos Corp Stock Faces Monthly Pressure Amid Analyst Optimism and Glaucoma Innovation Push - AD HOC NEWS
Piper Sandler reiterates Glaukos stock rating on growth outlook - Investing.com UK
Piper Sandler reiterates Glaukos stock rating on growth outlook By Investing.com - Investing.com Australia
Why is Glaukos (GKOS) down 14.7% since last earnings report? - MSN
JPMorgan Chase & Co. Has $54.65 Million Stock Position in Glaukos Corporation $GKOS - marketbeat.com
Glaukos Introduces Epioxa, Accelerating Expansion in Corneal Therapy - Bitget
Glaukos Announces Commercial Availability of Epioxa, a Transformative Innovation in Interventional Keratoconus Care - marketscreener.com
Glaukos Corp. Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators - Markets Mojo
Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments - Yahoo Finance Singapore
Glaukos (GKOS) Launches Epioxa HD for Keratoconus Treatment - GuruFocus
Glaukos Corporation (NYSE:GKOS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Glaukos Announces Commercial Availability of Epioxa for Incision-Free Keratoconus Care - VisionMonday.com
Glaukos SVP Thurman sells $61,968 in GKOS stock By Investing.com - Investing.com India
Navratil, Glaukos corp officer, sells $101k in GKOS stock By Investing.com - Investing.com Australia
Glaukos (NYSE:GKOS) CFO Alex Thurman Sells 625 Shares - MarketBeat
Glaukos SVP Thurman sells $61,968 in GKOS stock - Investing.com
Navratil, Glaukos corp officer, sells $101k in GKOS stock - Investing.com
Glaukos (NYSE: GKOS) CDO reports 1,031-share sale and tax withholding - Stock Titan
Glaukos (NYSE: GKOS) CFO sells 625 shares under 10b5-1 plan - Stock Titan
GLAUKOS (NYSE: GKOS) COO reports tax-withholding of 1,189 vested shares - Stock Titan
[Form 4] GLAUKOS Corp Insider Trading A... - Stock Titan
Glaukos' Epioxa now commercially available in the US - Eyes On Eyecare
Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care - BioSpace
Why Is Glaukos (GKOS) Down 14.7% Since Last Earnings Report? - Yahoo Finance
Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional - pharmiweb.com
Glaukos announces commercial availability of Epioxa for the treatment of keratoconus - Optometry Times
Glaukos Corporation Announces Commercial Availability Of Epioxa HD / Epioxa For Keratoconus Treatment - marketscreener.com
Glaukos Launches Epioxa for Keratoconus Treatment - marketscreener.com
Glaukos announces commercial availability of Epioxa HD/Epioxa - TipRanks
Glaukos Corporation (GKOS) 財務データ
収益
当期純利益
現金流量
EPS
Glaukos Corporation (GKOS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER |
Mar 24 '26 |
Sale |
105.24 |
1,521 |
160,070 |
46,498 |
大文字化:
|
ボリューム (24 時間):